Clinical interaction with patients and health care providers is crucial to the success ofthe research studies proposed within the SPORE and to the long-term success of translational ovarian cancer research. The Patient Recruitment, Enrollment and Characterization Core (referred to in this document as the Clinical Core) provides the clinical expertise and the physician and patient interaction which is necessary for the successful completion of the research objectives of the SPORE projects and pilot activities. The POCRC Clinical Core has demonstrated a strong track-record in recruiting large cohorts of women at risk for developing ovarian cancer (pre-diagnosis cohort) and women with ovarian cancer at the time of diagnosis (incident cases cohort) and during treatment and follow-up (post diagnosis cohort). Using uniform protocols to approach, consent, enroll, and track participants, over 3400 women have been enrolled into POCRC SPORE (n=1740) inter-SPORE (n=1112) and investigator initiated ROI funded (n= 637) ovarian cancer research projects. As in prior years, continued success ofthe Pacific Ovarian Cancer Research Consortium depends on the recruitment of participants into research studies including clinical trials. Building on our prior success and experience, the POCRC Clinical Core will refine participant contact and enrollment procedures to support all ofthe projects in this SPORE application as well as developmental research activities and collaborations within and outside ofthe SPORE. Working in concert-with the Clinical Specimen Management and Characterization Core and the Biostatistics and Informatics Core, the clinical core will identify participants for clinical trials and provide bio-specimens and associated clinical data that are necessary to meet the research objectives ofthe SPORE. The activities of the Clinical Core are expanding to include sites at Stanford University Medical Center, Palo Alto, California and City of Hope, Duarte, California. The addition of these sites is consistent with our goal of uniting major ovarian cancer research centers along the West Coast.

Public Health Relevance

The goal of this ovarian SPORE is to demonstrate better strategies for 1) screening high-risk women using novel serum markers and state-of-the-art imaging without the need for another large trial, by integrating our Phase 1 trial results with reports from ongoing Phase 111 efficacy trials;2) selecting women for neoadjuvant therapy by testing their blood for a resectability signature;and 3) immunizing women against their own tumors to prevent recurrence. Success in one or more of these efforts will significantly reduce the burden of ovarian cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fred Hutchinson Cancer Research Center
United States
Zip Code
Vragniau, Charles; Hübner, Jens-Martin; Beidler, Peter et al. (2017) Studies on the Interaction of Tumor-Derived HD5 Alpha Defensins with Adenoviruses and Implications for Oncolytic Adenovirus Therapy. J Virol 91:
Au-Yeung, George; Lang, Franziska; Azar, Walid J et al. (2017) Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. Clin Cancer Res 23:1862-1874
Liu, Joyce F; Palakurthi, Sangeetha; Zeng, Qing et al. (2017) Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. Clin Cancer Res 23:1263-1273
Kroeger Jr, Paul T; Drapkin, Ronny (2017) Pathogenesis and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol 29:26-34
Yu-Rice, Yi; Edassery, Seby L; Urban, Nicole et al. (2017) Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer. Reproduction 153:277-284
Zheng, Grace X Y; Terry, Jessica M; Belgrader, Phillip et al. (2017) Massively parallel digital transcriptional profiling of single cells. Nat Commun 8:14049
Liao, John B; Swensen, Ron E; Ovenell, Kelsie J et al. (2017) Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer. Gynecol Oncol 144:480-485
Labidi-Galy, S Intidhar; Papp, Eniko; Hallberg, Dorothy et al. (2017) High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun 8:1093
Kondrashova, Olga; Nguyen, Minh; Shield-Artin, Kristy et al. (2017) Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discov 7:984-998
Iwanicki, Marcin P; Chen, Hsing-Yu; Iavarone, Claudia et al. (2016) Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition. JCI Insight 1:

Showing the most recent 10 out of 185 publications